The patent has a natural expiration of 2045. Upon zervimesine’s approval by the U.S. Food and Drug Administration (FDA), the patent may be eligible for an extension of up to five additional years.

The patent, titled "Crystalline forms of 2-(tert-butoxy)-4-(3-methyl-3-(5-(methylsulfonyl)isoindolin-2-yl)butyl)phenol fumarate salt," has been assigned U.S. Patent No. 12,759,979.

The ‘979 patent offers the following protections:

Composition of Matter: a polymorphic crystalline form of zervimesine.
Production Process: a proprietary process for producing this form of zervimesine.
Therapeutic Methods: methods of treating the age-related degenerative disorders Alzheimer’s disease, dry age-related macular degeneration (dry AMD), and dementia with Lewy bodies (DLB)
 

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.